News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Alizyme PLC Successful Phase IIb Cetilistat Trial In Obese Diabetics
December 13, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Alizyme plc (LSE:AZM) is pleased to announce the preliminary results of its successful Phase IIb clinical trial of cetilistat in clinically obese diabetic patients.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Stomach cancer
Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer
January 7, 2026
·
2 min read
·
Tristan Manalac
Podcast
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
January 7, 2026
·
2 min read
·
Heather McKenzie
Insights
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
January 7, 2026
·
3 min read
·
Jennifer Smith-Parker
Weight Loss
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study
January 6, 2026
·
3 min read
·
Annalee Armstrong
